230 related articles for article (PubMed ID: 1689773)
1. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group.
Klepp O; Olsson AM; Henrikson H; Aass N; Dahl O; Stenwig AE; Persson BE; Cavallin-Ståhl E; Fosså SD; Wahlqvist L
J Clin Oncol; 1990 Mar; 8(3):509-18. PubMed ID: 1689773
[TBL] [Abstract][Full Text] [Related]
2. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA).
Klepp O; Flodgren P; Maartman-Moe H; Lindholm CE; Unsgaard B; Teigum H; Fosså SD; Paus E
Ann Oncol; 1990 Jul; 1(4):281-8. PubMed ID: 1702312
[TBL] [Abstract][Full Text] [Related]
3. Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project.
Klepp O; Olsson AM; Ous S; Nilsson S; Høisaether PA; Tveter K
Scand J Urol Nephrol; 1991; 25(3):179-90. PubMed ID: 1658924
[TBL] [Abstract][Full Text] [Related]
4. Observations after orchiectomy in clinical stage I nonseminomatous germ cell tumors of the testis.
Kuo JY; Chin T; Hsieh YL; Lin AT; Chang YH; Wei C; Chen KK; Chang LS
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jun; 62(6):356-61. PubMed ID: 10389293
[TBL] [Abstract][Full Text] [Related]
5. Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein.
Peterson M; Beck S; Bihrle R; Einhorn L; Foster R
BJU Int; 2009 Jul; 104(2):176-8. PubMed ID: 19493258
[TBL] [Abstract][Full Text] [Related]
6. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
Beck SD; Foster RS; Bihrle R; Donohue JP
Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
[TBL] [Abstract][Full Text] [Related]
7. Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer.
Klepp O; Dahl O; Flodgren P; Stierner U; Olsson AM; Oldbring J; Nilsson S; Daehlin L; Tørnblom M; Småland R; Starkhammar H; Abramsson L; Wist E; Raabe N; Edekling T; Cavallin-Ståhl E
Eur J Cancer; 1997 Jun; 33(7):1038-44. PubMed ID: 9376184
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
9. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
Ondrus D; Ondrusova M; Hornak M; Matoska J
Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
[TBL] [Abstract][Full Text] [Related]
10. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.
Steyerberg EW; Keizer HJ; Fosså SD; Sleijfer DT; Toner GC; Schraffordt Koops H; Mulders PF; Messemer JE; Ney K; Donohue JP
J Clin Oncol; 1995 May; 13(5):1177-87. PubMed ID: 7537801
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
Svatek RS; Spiess PE; Sundi D; Tu SM; Tannir NM; Brown GA; Kamat AM; Wood CG; Pisters LL
Cancer; 2009 Mar; 115(6):1310-7. PubMed ID: 19156903
[TBL] [Abstract][Full Text] [Related]
12. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis.
Amato RJ; Ro JY; Ayala AG; Swanson DA
Urology; 2004 Jan; 63(1):144-8; discussion 148-9. PubMed ID: 14751368
[TBL] [Abstract][Full Text] [Related]
13. Orchiectomy alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis.
Sogani PC; Whitmore WF; Herr HW; Bosl GJ; Golbey RB; Watson RC; DeCosse JJ
J Clin Oncol; 1984 Apr; 2(4):267-70. PubMed ID: 6200576
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
15. Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors.
Sheinfeld J; Motzer RJ; Rabbani F; McKiernan J; Bajorin D; Bosl GJ
J Urol; 2003 Oct; 170(4 Pt 1):1159-62. PubMed ID: 14501715
[TBL] [Abstract][Full Text] [Related]
16. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
17. Clinical stage I nonseminomatous germ cell tumors of the testis in childhood and adolescence: an analysis of 31 cases.
Terenziani M; Piva L; Spreafico F; Salvioni R; Massimino M; Luksch R; Cefalo G; Casanova M; Ferrari A; Polastri D; Mazza E; Bellani FF; Nicolai N
J Pediatr Hematol Oncol; 2002; 24(6):454-8. PubMed ID: 12218592
[TBL] [Abstract][Full Text] [Related]
18. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group.
Steyerberg EW; Keizer HJ; Messemer JE; Toner GC; Schraffordt Koops H; Fosså SD; Gerl A; Sleijfer DT; Donohue JP; Habbema JD
Cancer; 1997 Jan; 79(2):345-55. PubMed ID: 9010108
[TBL] [Abstract][Full Text] [Related]
19. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
20. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer.
Beck SD; Foster RS; Bihrle R; Ulbright T; Koch MO; Wahle GR; Einhorn LH; Donohue JP
J Urol; 2002 Oct; 168(4 Pt 1):1402-4. PubMed ID: 12352402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
